Clinical Research Directory

Inclusion Criteria: * Age ≥18 years * Patients with unresectable locally advanced T3-4 stage or M1 stage metastatic digestive system tumors confirmed by histology or cytology, including gastric cancer, colorectal cancer, hepatocellular carcinoma, biliary tract cancer and pancreatic cancer * Patients who have not received systematic treatment in the past or whose disease has progressed or is intolerant after standard first-line treatment, and whose disease has progressed for more than 6 months after neoadjuvant therapy/whose last adjuvant therapy failed/who have completed (new) adjuvant therapy for less than 6 months from disease recurrence can be enrolled * Histologically or cytologically confirmed HER2-positive (IHC 3+ or IHC 2+/FISH-amplified/NGS-confirmed) locally advanced or metastatic digestive system tumors (including gastric, colorectal, hepatocellular, biliary tract cancers) * ECOG performance status 0-2 * At least one measurable lesion per RECIST 1.1 criteria * Adequate organ function: * Hematologic: ANC ≥1.5×10⁹/L, platelets ≥75×10⁹/L, hemoglobin ≥9 g/dL * Hepatic: Total bilirubin ≤1.5×ULN; ALT/AST ≤2.5×ULN (≤5×ULN for liver metastases/HCC); albumin ≥28 g/L * Renal: Serum creatinine ≤1.5×ULN or CrCl ≥50 mL/min; urine protein \<2+ (if ≥2+, 24-hour urine protein \<1 g) * Coagulation: INR ≤2.3 or PT prolongation ≤6 seconds * Life expectancy ≥12 weeks * Fertile patients must use effective contraception during treatment and for 6 months after last dose * Willing and able to provide written informed consent Exclusion Criteria: * Previous treatment with any HER2-targeted therapy (e.g., trastuzumab) * History of hematologic malignancies * Pregnancy, lactation, or plans to become pregnant during study * Last anticancer therapy ≤28 days prior to enrollment or unresolved toxicities from prior therapy * Contraindications to immunotherapy including: * History of organ transplantation * Severe autoimmune diseases * Grade ≥4 immune-related adverse events from prior immunotherapy * Uncontrolled active infections * Use of systemic immunosuppressants (\>10 mg/day prednisone equivalent) within 14 days * Known hypersensitivity to PD-1 inhibitors, pyrotinib, or monoclonal antibodies * Participation in other clinical trials within 3 months * Symptomatic ascites, pleural or pericardial effusion requiring drainage * Life-threatening bleeding events within 3 months or arterial/venous thrombosis within 6 months (except stable catheter-related thrombosis) * History of pulmonary fibrosis, interstitial lung disease, or drug-related pneumonitis * Active tuberculosis requiring treatment or treated within past year * Major surgery within 4 weeks or unhealed surgical wounds * Severe dysfunction of major organs (heart, lungs, liver, kidneys, CNS) * Any other condition that may increase risk or interfere with study results as judged by investigator